Marc P Bonaca1, Deepak L Bhatt1, Eugene Braunwald1, Marc Cohen2, Philippe Gabriel Steg3, Robert F Storey4, Peter Held5, Eva C Jensen5, Marc S Sabatine6. 1. TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. 2. Cardiovascular Division, Department of Medicine, Newark Beth Israel Medical Center, Mount Sinai School of Medicine, New York, NY. 3. Université Paris-Diderot, Sorbonne-Paris Cité, INSERM U-698, Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Paris, France. 4. Department of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom. 5. AstraZeneca, Mölndal, Sweden. 6. TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. Electronic address: mbonaca@partners.org.
Abstract
BACKGROUND:P2Y12 receptor antagonist therapy is recommended in addition to ASA for up to 1 year after acute coronary syndrome to reduce ischemic events. In contrast, the benefit of long-term dual antiplatelet therapy beyond 1 year remains unclear. Ticagrelor is a potent, reversibly binding P2Y12 receptor-antagonist that has been shown to be superior to clopidogrel in patients with acute coronary syndromes for up to 1 year. STUDY DESIGN: PEGASUS-TIMI 54 is a randomized, double-blind, placebo-controlled, multinational clinical trial designed to evaluate the efficacy and safety of ticagrelor in addition to aspirin (75-150 mg) for the prevention of major adverse cardiovascular events in patients with a history of myocardial infarction and risk factors. Patients with a history of spontaneous myocardial infarction within 1 to 3 years are randomized in a 1:1:1 fashion to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or matching placebo, all with low dose ASA, until the end of the study. The primary endpoint is a composite of cardiovascular death, myocardial infarction, or stroke. Recruitment began in October 2010 and completed in April 2013 with a sample size of over 21,000 patients. The trial is planned to continue until the latest of either 1,360 adjudicated primary end points are accrued or the last patient randomized has been followed for at least 12 months. CONCLUSIONS: PEGASUS-TIMI 54 is investigating whether the addition of intensive antiplatelet therapy with ticagrelor to low-dose aspirin reduces major adverse cardiovascular events in high-risk patients with a history of myocardial infarction.
RCT Entities:
BACKGROUND:P2Y12 receptor antagonist therapy is recommended in addition to ASA for up to 1 year after acute coronary syndrome to reduce ischemic events. In contrast, the benefit of long-term dual antiplatelet therapy beyond 1 year remains unclear. Ticagrelor is a potent, reversibly binding P2Y12 receptor-antagonist that has been shown to be superior to clopidogrel in patients with acute coronary syndromes for up to 1 year. STUDY DESIGN:PEGASUS-TIMI 54 is a randomized, double-blind, placebo-controlled, multinational clinical trial designed to evaluate the efficacy and safety of ticagrelor in addition to aspirin (75-150 mg) for the prevention of major adverse cardiovascular events in patients with a history of myocardial infarction and risk factors. Patients with a history of spontaneous myocardial infarction within 1 to 3 years are randomized in a 1:1:1 fashion to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or matching placebo, all with low dose ASA, until the end of the study. The primary endpoint is a composite of cardiovascular death, myocardial infarction, or stroke. Recruitment began in October 2010 and completed in April 2013 with a sample size of over 21,000 patients. The trial is planned to continue until the latest of either 1,360 adjudicated primary end points are accrued or the last patient randomized has been followed for at least 12 months. CONCLUSIONS:PEGASUS-TIMI 54 is investigating whether the addition of intensive antiplatelet therapy with ticagrelor to low-dose aspirin reduces major adverse cardiovascular events in high-risk patients with a history of myocardial infarction.
Authors: Laura Mauri; Dean J Kereiakes; Robert W Yeh; Priscilla Driscoll-Shempp; Donald E Cutlip; P Gabriel Steg; Sharon-Lise T Normand; Eugene Braunwald; Stephen D Wiviott; David J Cohen; David R Holmes; Mitchell W Krucoff; James Hermiller; Harold L Dauerman; Daniel I Simon; David E Kandzari; Kirk N Garratt; David P Lee; Thomas K Pow; Peter Ver Lee; Michael J Rinaldi; Joseph M Massaro Journal: N Engl J Med Date: 2014-11-16 Impact factor: 91.245
Authors: M G Battelli; S Musiani; L Buonamici; S Santi; M Riccio; N M Maraldi; T Girbés; F Stirpe Journal: Cell Mol Life Sci Date: 2004-08 Impact factor: 9.261
Authors: Jaya Chandrasekhar; Benjamin Hibbert; Michael Froeschl; Derek So; Roxana Mehran; Michel Le May Journal: Eur J Clin Pharmacol Date: 2015-10-09 Impact factor: 2.953
Authors: Robert W Yeh; Dean J Kereiakes; Philippe Gabriel Steg; Stephan Windecker; Michael J Rinaldi; Anthony H Gershlick; Donald E Cutlip; David J Cohen; Jean-Francois Tanguay; Alice Jacobs; Stephen D Wiviott; Joseph M Massaro; Adrian C Iancu; Laura Mauri Journal: J Am Coll Cardiol Date: 2015-03-15 Impact factor: 24.094